Image source: The Motley Fool.
TAL Education Group (NYSE:TAL)Q3 2019 Earnings Conference CallJan. 24, 2019, 8:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Ladies and gentlemen, thank you for standing by, and welcome to the TAL Education Group Third Fiscal Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. (Operator Instructions) I must advise you that this conference is being recorded today, January 24, 2019.
I would now like to hand the conference over to your first speaker today, Ms. Echo Yan. Thank you. Please go ahead.
Echo Yan -- Head of Investor Relations
Thanks, operator. Thank you all for joining us today for TAL Education Group's third fiscal quarter 2019 earnings conference call. The earnings release was distributed earlier today and you may find a copy on the Company IR website or through the newswires. During this call, you will hear from Chief Financial Officer, Mr. Rong Luo and Linda Huo, Vice President of Finance. Following their prepared remarks, Mr. Luo and Ms. Huo will be available to answer your questions.
Top 10 Performing Stocks To Invest In Right Now: Abeona Therapeutics Inc.(ABEO)
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2015. We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha(TM) (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF(TM) (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com. Advisors' Opinion:
- [By Shane Hupp]
Abeona Therapeutics Inc (NASDAQ:ABEO) shares traded up 9.2% during mid-day trading on Friday . The company traded as high as $8.14 and last traded at $8.10. 657,079 shares were traded during mid-day trading, an increase of 65% from the average session volume of 399,426 shares. The stock had previously closed at $7.42.
- [By Logan Wallace]
Abeona Therapeutics (NASDAQ:ABEO) was given a $36.00 price target by analysts at Cantor Fitzgerald. The firm currently has a buy rating on the stock.
- [By Ethan Ryder]
Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have been assigned a consensus rating of “Buy” from the thirteen ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $29.44.
- [By Stephan Byrd]
Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.
Top 10 Performing Stocks To Invest In Right Now: PowerShares S&P SmallCap Information Technology Portfolio(PSCT)
PowerShares S&P SmallCap Information Technology Portfolio (the Fund) seeks investment results that correspond generally to the price and yield performance of an index called the S&P SmallCap 600 Capped Information Technology Index (the Index). The Index consists of common stocks of the United States information technology companies. These are companies that are principally engaged in the business of providing information technology-related products and services, including computer hardware and software, Internet, electronics and semiconductors, and communication technologies. The Index is compiled, maintained and calculated by Standard & Poor's Financial Services LLC. The Fund will normally invest at least 80% of its total assets in common stocks of small-capitalization information technology companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Fund's investment adviser is Invesco PowerShares Capital Management LLC. Advisors' Opinion:- [By ]
Overall, our Game-Changing Stocks portfolio has had a good run this year. Our closed positions for 2017 have, on average, returned 28.5% -- a much stronger result than what we've seen from the Russell 2000 index or from the PowerShares S&P Small Cap Information Technology Portfolio ETF (Nasdaq: PSCT), which returned 13% and 11% year-to-date, respectively. It's not a fair comparison, of course, because our closed positions all have different time frames, but it does stress the strong promise of game-changing stocks.
Top 10 Performing Stocks To Invest In Right Now: Tyson Foods Inc.(TSN)
Tyson Foods, Inc., together with its subsidiaries, engages in the production, distribution, and marketing of chicken, beef, pork, and prepared food products, as well as related allied products worldwide. The company?s Chicken segment involves in breeding and raising chickens, as well as processing live chickens into fresh, frozen, and value-added chicken products. Its Beef segment processes live fed cattle and fabricates dressed beef carcasses into primal and sub-primal meat cuts and case-ready products The company?s Pork segment involves in the processing live market hogs; and fabricating pork carcasses into primal and sub-primal cuts and case-ready products. Its Prepared Foods segment manufactures and markets frozen and refrigerated food products comprising pepperoni, bacon, beef and pork pizza toppings, pizza crusts, flour and corn tortilla products, appetizers, prepared meals, ethnic foods, soups, sauces, side dishes, meat dishes, and processed meats. The company mark ets and sells its products to grocery retailers, grocery wholesalers, meat distributors, warehouse club stores, military commissaries, industrial food processing companies, chain restaurants or their distributors, international export companies, and domestic distributors, as well as to foodservice operations, such as plant and school cafeterias, convenience stores, hospitals, and other vendors. Tyson Foods, Inc. also offers its allied products to the manufacturers of pharmaceuticals and technical products, as well as to pork processors. The company was founded in 1935 and is headquartered in Springdale, Arkansas.
Advisors' Opinion:- [By Shane Hupp]
Van ECK Associates Corp lowered its position in shares of Tyson Foods, Inc. (NYSE:TSN) by 9.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,599,395 shares of the company’s stock after selling 158,891 shares during the period. Van ECK Associates Corp’s holdings in Tyson Foods were worth $85,408,000 as of its most recent SEC filing.
- [By Shane Hupp]
Tyson Foods, Inc. (NYSE:TSN) – Jefferies Financial Group reduced their Q2 2019 earnings per share estimates for Tyson Foods in a research note issued on Wednesday, February 13th. Jefferies Financial Group analyst A. Jagdale now expects that the company will post earnings of $1.25 per share for the quarter, down from their prior estimate of $1.30. Jefferies Financial Group also issued estimates for Tyson Foods’ FY2020 earnings at $6.70 EPS and FY2021 earnings at $7.28 EPS.
- [By Shane Hupp]
Tyson Foods, Inc. (NYSE:TSN) – Analysts at Piper Jaffray Companies lowered their Q2 2019 EPS estimates for Tyson Foods in a note issued to investors on Thursday, February 7th. Piper Jaffray Companies analyst M. Lavery now anticipates that the company will post earnings per share of $1.22 for the quarter, down from their prior estimate of $1.35. Piper Jaffray Companies currently has a “Buy” rating and a $72.00 target price on the stock. Piper Jaffray Companies also issued estimates for Tyson Foods’ Q3 2019 earnings at $1.56 EPS, Q4 2019 earnings at $1.63 EPS, FY2019 earnings at $6.00 EPS, Q1 2020 earnings at $1.79 EPS, Q2 2020 earnings at $1.51 EPS, Q3 2020 earnings at $1.76 EPS, Q4 2020 earnings at $1.76 EPS, FY2020 earnings at $6.82 EPS and FY2021 earnings at $7.36 EPS.
Top 10 Performing Stocks To Invest In Right Now: C&F Financial Corporation(CFFI)
C&F Financial Corporation, incorporated on July 20, 1993, is a bank holding company. The Company owns and operates through its subsidiary, Citizens and Farmers Bank (the Bank or C&F Bank), which is an independent commercial bank. The Company's segments include Retail Banking, Mortgage Banking, Consumer Finance and Other. Its Other segment includes a full-service brokerage firm. The Bank's subsidiaries include C&F Mortgage Corporation and its subsidiaries Certified Appraisals LLC and Lender Solutions LLC; C&F Finance Company and its subsidiary C&F Remarketing LLC; C&F Wealth Management Corporation; C&F Insurance Services, Inc., and CVB Title Services, Inc. The Company conducts brokerage activities through C&F Wealth Management Corporation, insurance activities through C&F Insurance Services, Inc. and title insurance services through CVB Title Services, Inc. The Company also owns three non-operating subsidiaries, C&F Financial Statutory Trust II (Trust II), C&F Financial Statutory Trust I (Trust I), and Central Virginia Bankshares Statutory Trust I (CVBK Trust I).
The Company's investment portfolio consists of securities available for sale. The Company's total securities amount to approximately $214.10 million. The Company's deposits are principally provided by individuals and businesses located within the communities served. Its total deposits amount to approximately $1.04 billion.
Retail Banking
The Company provides retail banking services through C&F Bank. The Company provides retail banking services at its main office in West Point, Virginia, and 24 Virginia branches located over one each in Cartersville, Chester, Cumberland, Hampton, Mechanicsville, Newport News, Norge, Powhatan, Providence Forge, Quinton, Saluda, Sandston, West Point and Yorktown, over two in Williamsburg, approximately four in Richmond and over four in Midlothian. These branches provide a range of banking services to individuals and businesses. Its services include various types of checking ! and savings deposit accounts, as well as business, real estate, development, mortgage, home equity and installment loans. It also offers automated teller machines (ATMs), Internet and mobile banking, and debit and credit cards, as well as safe deposit box rentals, collection, notary public, electronic transfer and other customary bank services to its customers.
Through the Retail Banking segment, the Company engages in a range of lending activities, which include the origination of one- to four-family and multi-family residential mortgage loans, commercial real estate loans, construction loans, land acquisition and development loans, consumer loans and commercial business loans. The Retail Banking segment originates residential mortgage loans secured by first and second liens on properties located in its primary market area in southeastern and central Virginia. It offers various types of residential first mortgage loans in addition to traditional long-term, fixed-rate loans. The Retail Banking segment has a real estate construction lending program. It makes loans primarily for the construction of one- to four-family residences and multi-family dwellings. It also makes construction loans for office and warehouse facilities and other nonresidential projects, generally limited to borrowers that present other business opportunities for the Retail Banking segment.
The Company's Retail Banking segment makes land acquisition and development loans to builders and developers for acquiring unimproved land to be developed for residential building sites, residential housing subdivisions, multi-family dwellings and a range of commercial uses. The Retail Banking segment offers builder lines of credit to residential home builders to support their land and lot inventory needs. The Retail Banking segment's commercial business loan products include revolving lines of credit to provide working capital, term loans to finance the purchase of vehicles and equipment, letters of credit to guarantee pa! yment and! performance, and other commercial loans. The Retail Banking segment offers its customers home equity lines of credit that enable customers to borrow funds secured by the equity in their homes. The Retail Banking segment offers a range of consumer loans, including automobile, personal secured and unsecured, and loans secured by savings accounts or certificates of deposit. The Consumer Finance segment has an automobile dealer network through which it purchases installment contracts throughout its markets. Its total loans amount to approximately $901.46 million.
Mortgage Banking
The Company engages in residential mortgage lending through the Mortgage Banking segment. The Company conducts mortgage banking activities through C&F Mortgage Corporation (C&F Mortgage). C&F Mortgage provides mortgage loan origination services through approximately 10 locations in Virginia, two in Maryland and two in North Carolina. C&F Mortgage offers a range of residential mortgage loans, which are originated for sale generally to various investors, such as Wells Fargo Home Mortgage; Franklin American Mortgage Company; Penny Mac Corporation, and the Virginia Housing Development Authority (VHDA). C&F Bank may also purchase permanent loans from C&F Mortgage. C&F Mortgage originates conventional mortgage loans, mortgage loans insured by the Federal Housing Administration (the FHA), mortgage loans guaranteed by the United States Department of Agriculture (the USDA) and the Veterans Administration (the VA), and home equity loans. Through its subsidiary, Certified Appraisals LLC, C&F Mortgage provides ancillary mortgage loan origination services for residential appraisals, and through its subsidiary, Lender Solutions LLC, provides certain mortgage origination functions to third parties.
Consumer Finance
The Company engages in non-prime automobile lending through the Consumer Finance segment. The Company conducts consumer finance activities through C&F Finance Company (C&F Finance). ! C&F Finan! ce is a regional finance company providing automobile loans throughout Virginia and in portions of Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland, Missouri, New Hampshire, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas and West Virginia through its offices in Richmond and Hampton, Virginia, in Nashville, Tennessee and in Hunt Valley, Maryland. C&F Finance is an indirect lender that provides automobile financing through lending programs that are designed to serve customers in the non-prime market. C&F Finance generally purchases automobile retail installment sales contracts from manufacturer-franchised dealerships with used-car operations and through selected independent dealerships. C&F Finance selects the dealers based on the types of vehicles sold.
Advisors' Opinion:- [By Max Byerly]
C&F Financial Corp (NASDAQ:CFFI) Director J P. Causey, Jr. sold 4,353 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $62.17, for a total value of $270,626.01. Following the transaction, the director now directly owns 25,491 shares of the company’s stock, valued at approximately $1,584,775.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
- [By Shane Hupp]
News stories about C&F Financial (NASDAQ:CFFI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C&F Financial earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the financial services provider an impact score of 46.3252262902797 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Top 10 Performing Stocks To Invest In Right Now: Roadrunner Transportation Systems, Inc(RRTS)
Roadrunner Transportation Systems, Inc. provides asset-light transportation and logistics services. The company operates through three segments: Truckload Logistics (TL), Less-than-Truckload (LTL), and Global Solutions. The company's TL segment arranges pickup, delivery, freight consolidation, and inventory management of TL freight through its network of 48 TL service centers, 4 freight consolidation and inventory management centers, 23 company dispatch offices, and approximately 100 independent brokerage agents in the United States and Canada. It also offers temperature-controlled, dry van, intermodal drayage, and flatbed services; and specializes in the transport of automotive parts, refrigerated foods, poultry, and beverages, as well as on-demand expedited services. The company's LTL segment is involved in the pickup, consolidation, linehaul, deconsolidation, and delivery of LTL shipments in the United States, Mexico, Puerto Rico, and Canada through a network of 47 LTL service centers and approximately 180 third-party delivery agents. The company's Global Solutions segment offers domestic and international transportation and logistics solutions, including pricing, contract management, transportation mode and carrier selection, freight tracking, freight bill payment and audit, cost reporting and analysis, and dispatch. This segment also provides domestic and international air and ocean transportation, and customs brokerage services. Roadrunner Transportation Systems, Inc. is headquartered in Cudahy, Wisconsin.
Media headlines about Roadrunner Transportation Systems (NYSE:RRTS) have been trending positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Roadrunner Transportation Systems earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave media stories about the transportation company an impact score of 49.1890734987185 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days. Municipal Employees Retirement System of Michigan reduced its position in Roadrunner Transportation Systems Inc (NYSE:RRTS) by 18.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 138,320 shares of the transportation company’s stock after selling 32,190 shares during the period. Municipal Employees Retirement System of Michigan owned 0.36% of Roadrunner Transportation Systems worth $289,000 at the end of the most recent quarter. Roadrunner Transportation Systems, Inc. (NYSE: RRTS) shares dropped 15 percent to $1.8598. Office Depot, Inc. (NASDAQ: ODP) will replace Roadrunner Transportation Systems in the S&P SmallCap 600 on Monday, June 4. Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company's pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 (UX023) KRN23 is a fully human monoclonal antibody administered via subcutaneous injection that is designed to bind and reduce the biological activity of fibroblast growth factor 23 (FGF23), to increase abnormally low phosphate levels in patients with X-linked hypophosphatemia (XLH). Patients with XLH have low serum phosphate levels due to excessive phosphate loss into the urine, which is directly caused by the effect on kidney function of excess FGF23 production in bone cells. The Company is also developing KRN23 for the treatment of tumor-induced osteomalacia (TIO). TIO results from typically benign tumors that produce excess levels of FGF23, which can lead to severe hypophosphatemia, osteomalacia, bone fractures, fatigue, bone and muscle pain, and muscle weakness. The Company is conducting Phase II study. rhGUS (UX003) Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7), also known as Sly Syndrome. Patients with MPS 7 suffer from severe cellular and organ dysfunction that typically leads to death in the teens or early adulthood. MPS 7 is caused by a deficiency of the lysosomal enzyme beta-glucuronidase, which is required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). It has conducted preclinical studies to supp! ort the chronic IV administration of rhGUS. UX007 The Company is developing UX007 for oral administration intended as a substrate replacement therapy for patients with long-chain fatty acid oxidation disorders (LC-FAOD). UX007 is a purified, pharmaceutical-grade form of triheptanoin, a specially designed synthetic triglyceride compound, created via a multi-step chemical process. UX007 is a medium odd-chain triglyceride of over seven-carbon fatty acids designed to provide substrate replacement for fatty acid metabolism and restore production of energy. Patients with LC-FAOD have a deficiency that impairs the ability to produce energy from fat, which can lead to depletion of glucose in the body, and severe liver, muscle, and heart disease, as well as death. The Company has initiated Phase III study in LC-FAOD. The Company is also developing UX007 for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS is caused by a mutation affecting the gene that codes for Glut1, which is a protein that transports glucose from the blood into the brain. UX007 is intended as a substrate replacement therapy to provide an alternative source of energy to the brain in Glut1 DS patients. The Company has initiated a Phase III study in Glut1 DS patients with the movement disorder phenotype. Ace-ER (UX001) The Company is developing aceneuramic acid extended-release (Ace-ER), formerly known as sialic acid extended-release (SA-ER), which is an extended-release, oral formulation of sialic acid for the treatment of GNE myopathy, which is also known as hereditary inclusion body myopathy (HIBM). GNE myopathy is characterized by severe progressive muscular myopathy, or disease in which muscle fibers do not function properly, with onset typically in the late teens or twenties. Patients with GNE myopathy have a genetic defect in the gene coding for a particular enzyme that is involved in the first step in the biosynthesis of sialic acid. Ace-ER is intended a! s a subst! rate replacement therapy designed to address sialic acid deficiency and restore muscle function in GNE myopathy patients. The Company has conducted a Phase II randomized, double-blind, placebo-controlled study of Ace-ER in 47 GNE myopathy patients. rhPPCA (UX004) Recombinant human protective protein cathepsin-A (rhPPCA), which it in-licensed from St. Jude Children's Research Hospital, is in preclinical development as an enzyme replacement therapy for galactosialidosis, a rare lysosomal storage disease for which there are no approved drug therapies. Patients with galactosialidosis present with both soft tissue storage in the liver, spleen, and other tissues, as well as connective tissue (bone and cartilage) related disease. As with MPS 7, an enzyme deficiency results in accumulation of substrates in the lysosomes, causing skeletal and organ dysfunction, and death. It is continuing preclinical development of rhPPCA. The Company competes with B. Braun Medical Inc. BidaskClub downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a hold rating in a report released on Wednesday morning. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)Q4 2018 Earnings Conference CallFeb. 19, 2019, 5:00 p.m. ET Operator Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of Q3 earnings release.” China BAK Battery, Inc., together with its subsidiaries, engages in the manufacture, commercialization, and distribution of various standard and customized lithium ion rechargeable batteries. The company offers various products, including aluminum-case prismatic, cylindrical, lithium polymer, and high-power lithium battery cells. Its battery cells are the principal component of rechargeable batteries used to power cellular phones and smart phones; notebook computers, tablet computers, and e-book readers; portable consumer electronics, such as digital cameras, portable media players, portable gaming devices, personal digital assistants, camcorders, and Bluetooth headsets; and electric bicycles, light electric vehicles, hybrid electric vehicles, cordless power tools, and uninterruptible power supplies. The company serves battery pack manufacturers, original equipment manufactures, and replacement battery manufacturers primarily in the People?s Republic of China, Taiwan, Hon g Kong, India, the United States, the Middle East, Italy, Germany, and Turkey. China BAK Battery, Inc. was founded in 2001 and is based in Shenzhen, China. CBAK Energy Technology (NASDAQ:CBAK) and Electro Scientific Industries (NASDAQ:ESIO) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings. Maxwell Technologies (NASDAQ:MXWL) and CBAK Energy Technology (NASDAQ:CBAK) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Cracker Barrel Old Country Store, Inc., through its subsidiaries, engages in the development and operation of the Cracker Barrel Old Country Store restaurant and retail concept in the United States. Its restaurants provide breakfast, lunch, and dinner. The company?s gift shops offer various decorative and functional items, such as rocking chairs, holiday and seasonal gifts, apparel, toys, music CD?s, cookware, old-fashioned-looking ceramics, figurines, a book-on-audio sale-and-exchange program, and various other gift items, as well as candies, preserves, pies, cornbread mixes, coffee, syrups, pancake mixes, and other food items. As of November 22, 2011, it operated 608 company-owned locations in 42 states. The company was formerly known as CBRL Group, Inc. and changed its name to Cracker Barrel Old Country Store, Inc. in December 2008. Cracker Barrel Old Country Store, Inc. was founded in 1969 and is headquartered in Lebanon, Tennessee. Cracker Barrel Old Country Store Inc (NASDAQ:CBRL)Q2 2019 Earnings Conference CallFeb. 26, 2019, 11:00 a.m. ET Operator Watch him become $1,050 richer in 15 seconds… $940 richer in 11 seconds… $1,260 richer in eight seconds… and $988 richer in seven seconds! To see how easily this extra cash adds up, go here… In a recent show devoted to southern restaurant and gift store chain Cracker Barrel (NASDAQ:CBRL), the Motley Fool Industry Focus podcast team analyzes the company's juicy shareholder returns, which include rising dividend payments and, over the last few years, annual special dividends. While shareholders aren't likely to pass up these attractive payouts, would the money be better spent on new locations? Cracker Barrel (NASDAQ:CBRL) has treated its shareholders with a huge dose of southern hospitality, as shares have gained 24% annually on a total return basis over the last five years. The organization's relatively stable business model of attracting recurring restaurant visits from highway travelers, and enticing them to visit adjoining gift stores, implies a level of safety versus faster-growth companies. Still, red flags exist, and in the following segment from a recent Motley Fool Industry Focus podcast, we outline problem areas investors should be aware of. Transcanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Oil Pipelines, and Energy. The Natural Gas Pipelines segment develops and operates energy infrastructure, including natural gas pipelines and regulated gas storage facilities. Its network of natural gas pipelines extends approximately 60,000 km tapping into gas supply basins in North America. The Oil Pipelines segment operates Keystone crude oil pipeline system, which includes completed 3,467 km Wood River/Patoka and Cushing Extension phases, and the proposed 2,673 km U.S. Gulf Coast Expansion. The Energy segment engages in the acquisition, development, construction, ownership, and operation of electrical power generation plants; the purchase and marketing of electricity; the provision of electricity account services to energy and industrial customers; and the development, construction, ownership, and operation of non-regulat ed natural gas storage in Alberta. The company was founded in 1951 and is headquartered in Calgary, Canada. (NasdaqOTH: ANNSF) Data source: S&P Global. TransCanada (NYSE:TRP) has a long history of growing shareholder value. Overall, the Canadian pipeline giant has increased its dividend in each of the past 19 years -- including an 8.7% raise for 2019 -- which has helped fuel 12% total annual returns over that time frame. As a result of that steady diet of dividend increases, TransCanada currently offers an attractive 4.7% yield. Lions Gate Entertainment Corp., incorporated on April 28, 1997, is engaged in motion picture production and distribution, television programming and syndication, home entertainment, international distribution and sales, branded channel platforms, interactive ventures and games and location-based entertainment. The Company operates through two segments: Motion Pictures and Television Production. The Company's Motion Pictures segment consists of the development and production of feature films, acquisition of North American and around the world distribution rights, North American theatrical, home entertainment and television distribution of feature films produced and acquired, and around the world licensing of distribution rights to feature films produced and acquired. The Company's Television Production segment consists of the development, production and around the world distribution of television productions, including television series, television movies, and mini-series and non-fiction programming. Motion Pictures The Company's Motion Pictures segment is engaged in the domestic theatrical release of motion pictures licensed to theatrical exhibitors on a picture-by-picture basis (directly distributed by it in the United States and through a sub-distributor in Canada). It is engaged in the sale and rental of its film productions and acquired or licensed films and certain television programs (including theatrical and direct-to-video releases) to retail stores and through digital media platforms. The Company distributes a library of approximately 16,000 motion picture titles and television episodes and programs. It licenses its theatrical productions and acquired films to the linear pay, basic cable and free television markets. It is engaged in the licensing of productions, acquired films, catalog product and libraries of acquired titles from its international subsidiaries and distribution to international distributors, on a territory-by-territory basis. It has an interactive ve! ntures and games division and global franchise management and strategic partnerships division. It is also engaged in the sale and licensing of music from the theatrical exhibition of its films and the television broadcasts of its productions, and licensing of its films and television programs to ancillary markets. Television Production The Company's Television Production segment is engaged in the licensing and syndication of approximately one-hour and approximately half-hour scripted and unscripted series, television movies, mini-series and non-fiction programming. The Company is engaged in the sale or rental of television production movies or series on packaged media and through digital media platforms. Lions Gate Entertainment (NYSE:LGF.A) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday. ValuEngine cut shares of Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) from a sell rating to a strong sell rating in a research report released on Wednesday. ValuEngine upgraded shares of Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) from a strong sell rating to a sell rating in a research note published on Thursday morning. Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) had its price target decreased by analysts at Barrington Research to $27.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has an “outperform” rating on the stock. Barrington Research’s price objective suggests a potential upside of 17.60% from the stock’s previous close.Top 10 Performing Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)
Top 10 Performing Stocks To Invest In Right Now: China BAK Battery Inc.(CBAK)
Top 10 Performing Stocks To Invest In Right Now: Cracker Barrel Old Country Store Inc.(CBRL)
Top 10 Performing Stocks To Invest In Right Now: Transcananda Pipelines Ltd.(TRP)
Top 10 Performing Stocks To Invest In Right Now: (LGF.A)
No comments:
Post a Comment